BIRC5 and neoplasm: In fact, a large subset of patients classified with very favorable outcome shared a common molecular tumor phenotype characterized by ER-positive and/or ERBB2-negative status and low proliferation (low levels of E2F1 as well as BIRC5,TYMS,TOP2A and TK1).